{
    "clinical_study": {
        "@rank": "99223", 
        "arm_group": [
            {
                "arm_group_label": "YPEG-rhG-CSF 20\u03bcg/kg", 
                "arm_group_type": "Experimental", 
                "description": "20\u03bcg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle"
            }, 
            {
                "arm_group_label": "YPEG-rhG-CSF 30\u03bcg/kg", 
                "arm_group_type": "Experimental", 
                "description": "30\u03bcg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle"
            }, 
            {
                "arm_group_label": "YPEG-rhG-CSF 45\u03bcg/kg", 
                "arm_group_type": "Experimental", 
                "description": "45\u03bcg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle"
            }, 
            {
                "arm_group_label": "PEG-rhG-CSF 100\u03bcg/kg", 
                "arm_group_type": "Active Comparator", 
                "description": "100\u03bcg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to examine which dose of YPEG-rhG-CSF, once-per-cycle, has similar efficacy\n      and safety, comparing to PEG-rhG-CSF, once-per-cycle,  in chemotherapy-induced neutropenia"
        }, 
        "brief_title": "Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Non Small Cell Lung Cancer", 
            "Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of non-small cell lung cancer or Breast cancer, and adequate for\n             carboplatin combined with taxol or cyclophosphamide combined with pharmorubicin\n             chemotherapy\n\n          -  Karnofsky Score \u2265 70\n\n          -  Life Expectancy > 3 months\n\n          -  Age: 18\uff5e70yrs.\n\n          -  Peripheral blood test: WBC\u22653.5\u00d7106/mm3, PLT\u2265100\u00d7106/mm3, ANC\u22651.5\u00d7106/mm3; Normal bone\n             marrow function; Bone marrow biopsy shows active hematopoietic without cancer cells.\n\n          -  Normal coagulation function, no evidences of hemorrhage tendency.\n\n          -  No exiting diseases or condition that may influence drug absorption, distribution,\n             metabolism, and excretion.\n\n          -  Adequate liver, cardiac, kidney function. Indicators of liver function test \u2264 2.5ULN,\n             Indicators of kidney function test \u2264 1ULN\n\n          -  Understand and voluntarily sign an informed consent form.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating females\n\n          -  Evidence of tumor metastasis in bone marrow\n\n          -  Lack insight due to tumor metastasis in the central nervous system\n\n          -  Prior bone marrow transplant or stem cell transplant\n\n          -  Infective symptom before enrollment into this study\n\n          -  Other malignancy history\n\n          -  Known hypersensitivity to any component of the drug(e.g. rh-G-CSF) that to be\n             administered\n\n          -  Subject enrolled in any other investigational drug or device trial within 3 months of\n             informed consent date\n\n          -  Drug abuser or alcoholist\n\n          -  Prior radiotherapy or expected to received radiotherapy\n\n          -  Unstable or uncontrolled cardiac or hypertension\n\n          -  Other conditions which in the opinion of the investigator preclude enrollment into\n             the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005458", 
            "org_study_id": "TB1309CSF"
        }, 
        "intervention": [
            {
                "arm_group_label": "YPEG-rhG-CSF 20\u03bcg/kg", 
                "intervention_name": "YPEG-rhG-CSF, 20\u03bcg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "YPEG-rhG-CSF 30\u03bcg/kg", 
                "intervention_name": "YPEG-rhG-CSF, 30\u03bcg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "YPEG-rhG-CSF 45\u03bcg/kg", 
                "intervention_name": "YPEG-rhG-CSF, 45\u03bcg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PEG-rhG-CSF 100\u03bcg/kg", 
                "intervention_name": "PEG-rhG-CSF, 100\u03bcg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Neutropenia", 
            "Febrile neutropenia", 
            "PEG-rhG-CSF", 
            "Myelosuppressive chemotherapy"
        ], 
        "lastchanged_date": "December 6, 2013", 
        "location": {
            "contact": {
                "email": "clinical@amoytop.com", 
                "last_name": "Wang Runhua, Ph.D", 
                "phone": "86-592-6889121"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Cancer Institute and Hospital, CAMS"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Multi-center, Randomized, Open-labeled, Positive-controlled, Phase \u2161 Study to Evaluate Efficacy and Safety of YPEG-rhG-CSF, Once-per-cycle, Comparing to PEG-rhG-CSF, Once-per-cycle, in Chemotherapy-induced Neutropenia of Patients With Malignancies Receiving Myelosuppressive Chemotherapy.", 
        "overall_contact": {
            "last_name": "Yuankai Shi, Ph.D", 
            "phone": "8610-87788701"
        }, 
        "overall_official": {
            "affiliation": "Cancer Institute and Hospital, CAMS", 
            "last_name": "Yuankai Shi, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administrition", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Grade 3 and 4 neutropenia means absolute neutrophil count is less than 1000/mm3 and 500/mm3 , respectively", 
            "measure": "Incidence of Grade 3 &4 neutropenia, and median duration of neutropenia in the two experimental cycles", 
            "safety_issue": "Yes", 
            "time_frame": "21 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005458"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Febrile neutropenia means absolute neutrophil count is less than 500/mm3 or absolute neutrophil count between 500/mm3 and 1000mm3 but probably to decline to less than 500mm3 within 48hrs, and body temperature is higher than 38.5 degrees celsius or higher than 38.0 degrees celsius and lasting for more than 1hr", 
                "measure": "Incidence of febrile neutropenia in the two experimental cycles", 
                "safety_issue": "Yes", 
                "time_frame": "21 day"
            }, 
            {
                "measure": "Diversification of neutrophil in the two experimental cycles", 
                "safety_issue": "No", 
                "time_frame": "21 day"
            }
        ], 
        "source": "Xiamen Amoytop Biotech Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xiamen Amoytop Biotech Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}